CClinicalTrials.gg
Sign In
Status unknownNCT03132558Updated Nov 7, 2017

Contrast Induced Acute Kidney in Patients With Acute Stroke

An observational study in Stroke, Acute, sponsored by Nanjing Medical University. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2017-11-07.

Sponsored by Nanjing Medical University · Observational

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
All
01

Study summary

Computed tomographic angiography (CTA) is recommended for identifying eligible patient with acute ischemic stroke (AIS) to receieve endovascular treatment. We are going to conduct this prospective corhot study to observe if sequential use contrast in CTA examination and in endovascular treatment will cause acute kidney injury.

02

Conditions studied

  • Stroke, Acute

Browse trials for

03

In context

Stroke

7,283 studies on the registry are indexed under Stroke; 2,013 are open to participants now.

This study's planned enrollment of 200 is above the median of 160 across 1,692 observational studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Nanjing Medical University is the lead sponsor of 169 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients who are suspected with AIS. Non-contrast head CT excludes intracranial hemorrhage. Patients who receieve CTA or CTA+DSA will be included in this study.

Inclusion criteria

  • All patients who are suspected with AIS.
  • Non-contrast head CT excludes intracranial hemorrhage.

Exclusion criteria

Exclusion Criteria:

  • Lacking of pre-CTA Creatinine
  • Lacking of post-angiography Creatinine with 24-48 hours
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • CTA

    Patients with AIS only receieved cerebral CTA exam.

    Drug: Radiopaque Media

  • CTA+DSA

    Patients with AIS receieved cerebral CTA, followed by endovascular treatment with the guidence of digital substration angiography (DSA).

    Drug: Radiopaque Media

Interventions

  • DrugRadiopaque Media
06

What researchers measure

Primary outcomes

  1. Creatinine

    Contrast-induced acute kidney injury was defined as a relative increase of 25% or an absolute increase of 0.3 mg/dL (28.2mol/L) in the serum creatinine level at 48 hours following angiography

    Time frame: within 24h to 48h

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210009, China
    • Hai Bin Shi · Contact · shihb@njmu.edu.cn
    • Haibin Shi, MD, PhD. · Principal investigator
    Recruiting
08

References and documents

Publications

  • Jia ZY, Wang SX, Zhao LB, Cao YZ, Shi HB, Liu S. Risk of Acute Kidney Injury with Consecutive, Multidose Use of Iodinated Contrast in Patients with Acute Ischemic Stroke. AJNR Am J Neuroradiol. 2019 Apr;40(4):652-654. doi: 10.3174/ajnr.A5959. Epub 2019 Jan 24. PubMed 30679214 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03132558
Lead sponsor
Nanjing Medical University
Responsible party
Hai-Bin Shi (Professor, Nanjing Medical University) — Principal investigator
First posted
Apr 28, 2017
Start date
Sep 2016
Primary completion
Sep 2017
Completion
Dec 2017 (estimated)
Last update
Nov 7, 2017

Study contacts

HaiBin Shi, MD.
Contact
shihb@njmu.edu.cn

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Stroke→

Other studies from this sponsor

Nanjing Medical University

Start the discussion